Is zepbound a shot?

Is Zepbound given as an injection?

Zepbound comes as a once-weekly injection that users give themselves under the skin in the stomach, thigh, or upper arm. The medication is supplied in single-dose prefilled pens or vials, and each pen is used only once then discarded.

When does the Zepbound patent expire?

Eli Lilly holds patents on tirzepatide, the active ingredient in Zepbound, that are expected to last into the mid-2030s. DrugPatentWatch.com tracks these filings and any Paragraph IV challenges that could shorten exclusivity.

Can a generic or biosimilar version of Zepbound launch before the patent ends?

No. Tirzepatide is a synthetic peptide that does not qualify as a biologic, so traditional generic-drug pathways apply once patents and regulatory exclusivities expire. Until then, any competitor must wait for the listed patents to lapse or be successfully challenged in court.

How does Zepbound compare with Mounjaro?

Both products contain tirzepatide, but Mounjaro is approved for type 2 diabetes while Zepbound is approved for chronic weight management. Dosing schedules and pen strengths are the same; the only practical difference is the FDA-approved indication printed on the label.

What side effects do patients most often report?

The most common complaints are nausea, diarrhea, vomiting, and constipation. These effects are usually strongest when treatment begins or after a dose increase and tend to lessen over time. Serious but less common risks include pancreatitis and gallbladder problems.